Is there a better risk reward in biotech?
...."in the next couple days".....seems a bit of an understatement, there are over 7M shares short!
Sentiment: Strong Buy
This company knows how to get partnerships.
With Tubulysin, 100 times more potent warhead, they will sure re-start the work on ovarian cancer. Then we will have ovarian, breast, lung and prostate cancer trials going on. Too cheap here at 6.34